Compositions and methods to inhibit restenosis
Disclosed herein are compositions and methods comprising a polysaccharide in combination with a pharmaceutical agent wherein the composition can be used to prevent restenosis.
1 . A composition for preventing restenosis, comprising one or more polysaccharides in combination with one or more pharmaceutical agents.
2 . The composition of claim 1 , wherein said polysaccharide is selected from the group consisting of galactomannan, arabinogalactan, rhamnogalacturon, carrageenan, locust bean gum and combinations thereof.
3 . The composition of claim 2 , wherein said polysaccharide is galactomannan.
4 . The composition of claim 1 , wherein said pharmaceutical agent is an anti-proliferative, anti-angiogenic, anti-cancer agent or combinations thereof.
5 . The composition of claim 4 , wherein said anti-cancer agent is selected from the group consisting of Aminoglutethimide, Amsacrine Anastrozole, Asparaginase, Bicalutamide, Bleomycin, Buserelin, Busulfan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clodronate, Cyclophosphamide, Cyproterone, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, dexamethasone, Diethylstilbestrol, Docetaxel, Doxorubicin, Epirubicin, Estramustine, Etoposide, Exemestane, Filgrastim, Fludarabine, Fludrocortisone, Fluorouracil, Fluoxymesterone, Flutamide, Gemcitabine, Goserelin, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Interferon-α, Irinotecan, Letrozole, Leucovorin, Leuprolide, Levamisole, Lomustine, Mechlorethamine, Medroxyprogesterone, Megestrol, Melphalan, Mercaptopurine, Mesna, methamycins, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilutamide, Octreotide, Oxaliplatin, Paclitaxel, Pamidronate, Pentostatin, Plicamycin, Porfimer, Procarbazine, Raltitrexed, Rituximab, Streptozocin, Tamoxifen, Temozolomide, Teniposide, Testosterone, Thioguanine, Thiotepa, Topotecan, Trastuzumab, Tretinoin, Vinblastine, Vincristine, Vindesine, Vinorelbine, daunomycin, doxorubicin, and combinations thereof.
6 . The composition of claim 4 , wherein said anti-proliferative agent is taxane.
7 . The composition of claim 6 , wherein said taxane is selected from the group consisting of C 47 H 51 No 14 ,C 47 H 51 NO 14 , including [2aR-[2α,4.β.,4α.,β.6.β,9. α(αR*,β.S*), 11α.,12α.,12Aα.,12α.,]]-β-(Benzoylamino)-α-hydroxybenzene propanoic acid 6,12b,bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a, 12b-dode cahydro4,11-dihydroxy4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca [3,4]benz-[1,2-b]oxet-9-yl ester and combinations thereof.
8 . The composition of claim 1 , wherein said restenosis is percutaneous transluminal coronary angioplasties.
9 . An implantable device comprising a surface coated with a composition having one or more polysaccharides and one or more pharmaceutical agents.
10 . The device of claim 9 , wherein said polysaccharide is selected from the group consisting of galactomannan, arabinogalactan, rhamnogalacturon, carrageenan, locust bean gum and combinations thereof.
11 . The device of claim 10 , wherein said polysaccharide is galactomannan.
12 . The device of claim 9 , wherein said pharmaceutical agent is an anti-proliferative, anti-angiogenic, anti-cancer agent or combinations thereof.
13 . The device of claim 9 , wherein said device is an angioplastic device.
14 . The device of claim 13 , wherein said angioplastic device is a cardiac stent.
15 . A method for preventing restenosis, comprising administering to a subject in need a composition having one or more polysaccharides in combination with one or more pharmaceutical agents, wherein said combination has reduced toxicity.
16 . The method of claim 15 , wherein said polysaccharide is selected from the group consisting of galactomannan, arabinogalactan, rhamnogalacturon, carrageenan, locust bean gum and combinations thereof.
17 . The method of claim 16 , wherein said polysaccharide is galactomannan.
18 . The method of claim 15 , wherein said pharmaceutical agent is an anti-proliferative, anti-angiogenic, anti-cancer agent or combinations thereof.
19 . The method of claim 18 , wherein said anti-cancer agent is selected from the group consisting of Aminoglutethimide, Amsacrine Anastrozole, Asparaginase, Bicalutamide, Bleomycin, Buserelin, Busulfan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clodronate, Cyclophosphamide, Cyproterone, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, dexamethasone, Diethylstilbestrol, Docetaxel, Doxorubicin, Epirubicin, Estramustine, Etoposide, Exemestane, Filgrastim, Fludarabine, Fludrocortisone, Fluorouracil, Fluoxymesterone, Flutamide, Gemcitabine, Goserelin, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Interferon-α, Irinotecan, Letrozole, Leucovorin, Leuprolide, Levamisole, Lomustine, Mechlorethamine, Medroxyprogesterone, Megestrol, Melphalan, Mercaptopurine, Mesna, methamycins, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilutamide, Octreotide, Oxaliplatin, Paclitaxel, Pamidronate, Pentostatin, Plicamycin, Porfimer, Procarbazine, Raltitrexed, Rituximab, Streptozocin, Tamoxifen, Temozolomide, Teniposide, Testosterone, Thioguanine, Thiotepa, Topotecan, Trastuzumab, Tretinoin, Vinblastine, Vincristine, Vindesine, Vinorelbine, daunomycin, doxorubicin, and combinations thereof.
20 . The method of claim 18 , wherein said anti-proliferative agent is taxane.
21 . The method of claim 20 , wherein said taxane is selected from the group consisting of C 47 H 51 ,No 14 ,C 47 H 51 NO 14 , including [2aR-[2aα,4.β.,4α.,β.6.β,9.α(αR*,β.S*), 11α., 12α., 12Aα., 12α.,]]-β-(Benzoylamino)-α-hydroxybenzene propanoic acid 6,12b,bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a, 12b-dode cahydro4,11-dihydroxy4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca [3,4]benz-[1,2-b]oxet-9-yl ester and combinations thereof.
22 . The method of claim 15 , wherein said restenosis is percutaneous transluminal coronary angioplasties.
23 . The method of claim 15 , wherein said administration of said polysaccharide and pharmaceutical agent are in a ration of about 10:1 to about 1:10 polysaccharide to pharmaceutical agent.
24 . The method of claim 15 , wherein said polysaccharide has a molecular weight ranging from about 2 kDa to about 300 kDa.
25 . The method of claim 15 , wherein said polysaccharide is a sulfated polysaccharide.
26 . The method of claim 25 , wherein said sulfated polysaccharide is selected from the group consisting of chondroitin sulfate, heparin sulfate, galactosaminglucuronate sulfate and a combination thereof.